Could a common steroid save lives in severe lung failure?
NCT ID NCT07576660
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether the steroid dexamethasone, when added to standard care, can lower the chance of death within 90 days for people with a serious lung condition called ARDS caused by sepsis. About 1,474 adults on breathing machines will take part. The goal is to see if this anti-inflammatory drug helps more people survive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongda Hospital, School of Medicine, Southeast University
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues may unlock better ECMO care for lung failure patients
- New study aims to Fine-Tune ventilator strategies for ARDS patients
- Can the right dose and timing of steroids save more lives in ARDS?
- New inflatable cushion could revolutionize ICU patient repositioning
- Tailored breathing support may reduce lung injury in ECMO patients
- ARDS ventilator tool faces reliability test